GET DAILY SIGNALSRenovoRx (RNXT) Delivers Record Q3 Revenue as Commercial Network Expands
Key Takeaways
- RenovoRx reported record third quarter 2026 revenue of approximately $1.07 million, up roughly 17% sequentially and more than four times the $266,000 recorded a year earlier.
- Net loss per share was $0.08, in line with the $0.08 loss reported in the prior-year quarter and slightly below the consensus estimate of a $0.07 loss.
- Management maintained its full-year 2026 revenue guidance of $3.75 million to $4.25 million, implying year-over-year growth of roughly 241% to 286%.
- Cash and cash equivalents stood at approximately $10.4 million, which the company expects to fund operations into the second half of 2027.
- The commercial footprint continued to expand, with active cancer centers growing from 21 to 26 and the total commercial funnel surpassing 65 centers.
Earnings Context and Why It Matters
RenovoRx, a life sciences company commercializing the FDA-cleared RenovoCath drug-delivery device, sits at an inflection point between its early commercialization ramp and its pivotal clinical program. The third quarter marked the company's first time exceeding $1 million in quarterly revenue, a milestone that signals growing adoption of its Trans-Arterial Micro-Perfusion (TAMP) platform for difficult-to-treat tumors such as locally advanced pancreatic cancer. With the Phase III TIGeR-PaC trial fully enrolled and top-line data expected in the second half of 2027, I am watching closely to see whether the commercial business can scale while clinical catalysts approach. This report offers a key read on demand momentum, margin quality, and the durability of the company's cash runway. I also checked this using Tickeron's AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, RenovoRx reported record revenue of approximately $1.07 million, compared with $266,000 in the same period of 2025. Gross profit was $878,000, reflecting a gross margin of roughly 82%. Research and development expenses were approximately $1.2 million, down from $1.7 million a year earlier, while selling, general, and administrative expenses rose to approximately $2.9 million from $1.7 million as the company invested in its commercial infrastructure. Loss from operations was approximately $3.2 million, essentially unchanged year over year, and net loss per share was $0.08, matching the prior-year figure.
Relative to expectations, revenue was broadly in line with the consensus estimate of roughly $1.06 million, while the $0.08 net loss per share came in modestly below the consensus estimate of a $0.07 loss. The company reiterated its full-year 2026 revenue guidance of $3.75 million to $4.25 million. From what I see, the results underscore steady progress on the commercial side even as operating losses persist.
Market Reaction and Investor Sentiment
Heading into the report, sentiment around RenovoRx reflected growing optimism about its commercial ramp, supported by the company's Q2 revenue beat and its raised full-year outlook. The record third-quarter revenue reinforces the narrative of accelerating adoption, even as the slight earnings miss and ongoing operating losses remind investors that the company remains pre-profitability. Post-earnings attention has centered on the pace of commercial center activation, the stability of gross margins above 80%, and the strength of the balance sheet, which management indicates is sufficient to fund operations into the second half of 2027. Key risk factors include the lumpiness of early-stage device revenue and execution on the company's target of expanding its active center network through year-end.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will watch whether RenovoRx can sustain its commercial momentum and convert its growing pipeline of more than 65 centers into active, revenue-generating accounts. Management has signaled confidence by reaffirming its 2026 revenue guidance, and the fourth quarter will be a key test of that trajectory.
On the clinical front, the completed enrollment of the Phase III TIGeR-PaC trial positions the company for a top-line data readout expected in the second half of 2027. That catalyst has the potential to meaningfully reshape the investment case by providing evidence on survival, safety, and tolerability for its targeted chemotherapy delivery approach.
Investors should also monitor cost trends, particularly selling, general, and administrative expenses tied to the commercial buildout, as well as gross margin stability. The company's path to cash-flow breakeven, previously framed around a $5 million quarterly revenue run rate, will be an important indicator of operating leverage as adoption scales. One thing that stands out is the cash position supporting operations well into 2027.
My Experience with Tickeron AI Tools
In my research process, I frequently use Tickeron's AI Screener to quickly filter stocks by technical patterns, fundamentals, and performance metrics. It helps surface relevant opportunities and compare names like RenovoRx against peers without spending hours on manual analysis. This tool has become a practical part of how I stay on top of earnings-driven moves and industry trends.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
RNXT's RSI Oscillator ascends from oversold territory
The RSI Indicator for RNXT moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 31 of the 33 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Momentum Indicator moved above the 0 level on October 23, 2026. You may want to consider a long position or call options on RNXT as a result. In 77 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for RNXT just turned positive on October 23, 2026. Looking at past instances where RNXT's MACD turned positive, the stock continued to rise in 40 of 48 cases over the following month. The odds of a continued upward trend are 83%.
Following a +3.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where RNXT advanced for three days, in 200 of 236 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
RNXT moved below its 50-day moving average on October 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for RNXT crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNXT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
RNXT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for RNXT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. RNXT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.981) is normal, around the industry mean (2.904). P/E Ratio (-3.839) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (31.250) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNXT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement